MeiraGTx has taken a significant step towards advancing its gene therapy for eye disease by reacquiring the rights to bota-vec from Johnson & Johnson (J&J). This development comes despite a challenging Phase 3 trial, which did not yield the expected results last year. The company is determined to leverage existing data to pursue regulatory approvals in the U.S. and EU by 2027.
The Acquisition Deal
Under the terms of the agreement, J&J will transfer the rights to bota-vec for an upfront payment of $25 million. Additionally, MeiraGTx will owe a one-time milestone payment upon receiving U.S. approval and will also need to meet certain sales performance benchmarks. J&J is set to receive royalties starting in mid-2029.
The partnership between MeiraGTx and J&J began in 2019, when J&J made an initial investment of $100 million, with the potential for the entire deal to reach up to $440 million, including various milestone payments. Throughout this collaboration, J&J has led the clinical development of bota-vec, while MeiraGTx has contributed significantly from Phase 1 onwards.
Challenges and Opportunities
The LUMEOS trial, which focused on bota-vec, faced setbacks when it failed to demonstrate improved visual-guided mobility among patients. Despite this, MeiraGTx remains optimistic about the data collected during the trial. The company believes there are still compelling arguments for regulatory approval based on the trial’s findings.
Experts, including Rachel Huckfeldt, a principal investigator in the trial, have pointed out that there were improvements in visual acuity as measured by standard reading tests. Furthermore, patients reported enhancements in their daily activities, underscoring the potential benefits of the therapy for individuals suffering from X-linked retinitis pigmentosa, a genetic condition that leads to blindness, particularly in males.
Expert Support for Regulatory Approval
Advocates for the therapy have rallied around MeiraGTx’s efforts, emphasizing the urgent need for effective treatments for patients with X-linked retinitis pigmentosa. The company has garnered support from various healthcare professionals who are eager to see bota-vec become available to those currently waiting for treatment options.
MeiraGTx has expressed its commitment to moving forward swiftly with the regulatory process now that it has regained control of bota-vec. The company is optimistic about filing for approval in both the U.S. and EU by 2027, marking a critical milestone in the development of this gene therapy.
Leadership’s Vision
Alexandria Forbes, CEO of MeiraGTx, articulated the excitement surrounding the reacquisition, stating that it represents a unique opportunity to advance a promising asset with data suggesting meaningful patient benefits. Forbes emphasized the importance of expeditious approval for this therapy, noting that many patients currently lack viable treatment options.
The successful approval of bota-vec would signify an important transition for MeiraGTx, moving the company into the ranks of commercial-stage biotechs. Their pipeline also includes another promising product, AAV-hAQP1, aimed at treating radiation-induced xerostomia, with pivotal trial results expected in the second quarter of 2027.
Future Outlook
As MeiraGTx gears up for regulatory submissions, the prospect of launching two significant products within the next two years is an exciting development for the company. This strategic move not only enhances their therapeutic offerings but also positions them favorably in the competitive landscape of gene therapies.
In summary, the reacquisition of bota-vec marks a pivotal moment for MeiraGTx. The company is poised to navigate the regulatory landscape with renewed determination and a commitment to addressing the unmet needs of patients suffering from X-linked retinitis pigmentosa.
- Key Takeaways:
- MeiraGTx reacquired bota-vec from J&J for $25 million.
- The company aims for regulatory approvals in the U.S. and EU by 2027.
- Despite a failed trial, MeiraGTx believes in the therapy’s potential benefits.
- Expert support underscores the urgent need for treatment options in XLRP.
- MeiraGTx also has another product, AAV-hAQP1, targeting xerostomia, expected to yield pivotal results soon.
Read more → www.biospace.com